Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Deramiocel (CAP-1002)

Phase 3Biologic

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscular DystrophiesActive, not recruiting

Muscular DystrophiesPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Muscular Dystrophies

NCT05126758

Clinical

Trials by Indication[1]

Trial1 trial

Open-label Extension of the HOPE-2 Trial

Active, not recruiting·CCapricor Inc.·Phase 2·NCT04428476·13 enrolled

Muscular Dystrophies1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

Active, not recruiting·CCapricor Inc.·Phase 3·NCT05126758·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Deramiocel (CAP-1002). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Deramiocel (CAP-1002) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Deramiocel (CAP-1002). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Capricor Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCapricor Inc.

Related News